MHRA GLP Compliance Programme MemberLast inspected March 2025

UKAS Accredited to ISO/IEC 17025UKAS Testing Laboratory No. 8821

Home Office Controlled Drugs Licence

HTA licencenot required for routine blood/plasma/urine bioanalysis

Lab technician microscope
01 / 07

LC-MS/MS Small Molecule Bioanalysis

Quantitative small-molecule bioanalysis by LC-MS/MS, validated to ICH M10, LLOQ down to pg/mL.

Quantitative determination of small-molecule drug and metabolite concentrations in plasma, serum, urine and other matrices by triple-quadrupole LC-MS/MS. Methods are developed and fully validated to ICH M10 (2022) before sample analysis begins, with a validation report issued ahead of the study report.

Typical validated LLOQ ranges from low pg/mL to ng/mL depending on analyte and matrix; each method's validated range, precision and accuracy data are set out in the validation report, not summarised as a single headline figure.

  • Triple-quadrupole LC-MS/MS platforms
  • Full ICH M10 (2022) method validation
  • LLOQ from low pg/mL, analyte-dependent
  • Validation report issued before sample analysis
From£8,400typical full method validation, small molecule
Laboratory scientist
02 / 07

Ligand-Binding Assays (LBA)

Ligand-binding assay development and validation for large-molecule and biomarker quantification.

Ligand-binding assay development for large-molecule therapeutics and endogenous biomarkers, using ELISA and electrochemiluminescence platforms, validated against the large-molecule bioanalytical provisions of ICH M10.

  • ELISA and electrochemiluminescence platforms
  • Large-molecule and biomarker quantification
  • Validated against ICH M10 large-molecule provisions
  • Cross-reactivity and matrix interference assessed
From£11,200typical full method validation, ligand-binding assay
Bioanalytical lab equipment
03 / 07

PK/TK Study Bioanalysis

Sample analysis support for pharmacokinetic and toxicokinetic studies, GLP and non-GLP.

Bioanalytical sample analysis for pharmacokinetic and toxicokinetic studies, run under our GLP quality system where the study requires it, or to an equivalent internal standard for discovery-phase non-GLP work. Turnaround is agreed at study initiation and tracked against the study protocol timeline.

  • GLP and non-GLP study support
  • Turnaround agreed at study initiation
  • Study director named and contactable throughout
  • Compliant with study protocol and SAP requirements
From£95per sample, volume-dependent, from
Scientist pipette lab
04 / 07

Immunogenicity Testing (ADA/NAb)

Anti-drug antibody and neutralising antibody assay development for biologics immunogenicity assessment.

Tiered anti-drug antibody (ADA) screening, confirmation and titration assays, with neutralising antibody (NAb) assays developed where a biologic's immunogenicity risk assessment requires them, following current regulatory expectations for a tiered testing strategy.

  • Tiered ADA screening, confirmation, titration
  • Neutralising antibody (NAb) assay development
  • Cut-point determination per current regulatory guidance
  • Reported alongside PK data where required
From£13,500typical tiered ADA assay development
Lab technician microscope
05 / 07

Method Development & Validation

Bespoke bioanalytical method development where no validated method exists for a novel analyte or matrix.

For novel analytes, unusual matrices or combination methods, we develop and validate a bespoke bioanalytical method from first principles, scoped and quoted before development work begins so there's no open-ended development fee.

  • Bespoke method development from first principles
  • Scoped and fixed-quoted before work begins
  • Novel analyte and unusual matrix experience
  • Full ICH M10 validation on completion
From£6,500scoped fixed fee, method development
Laboratory scientist
06 / 07

Sample Management & Storage

Chain-of-custody sample receipt, -80°C storage and controlled-drugs handling under Home Office licence.

Sample receipt, chain-of-custody logging and long-term storage down to -80°C, with continuous temperature monitoring and alarm escalation. Where a study involves controlled substances, handling is conducted under our Home Office Controlled Drugs Licence, covering Schedule 2-5 substances relevant to bioanalytical work.

  • Full chain-of-custody sample receipt
  • -80°C storage, continuously monitored
  • Home Office Controlled Drugs Licence held
  • Retention periods agreed per study protocol
From£4per sample, per month storage, from
Bioanalytical lab equipment
07 / 07

GLP Study Reporting & QA Audit

Full GLP study reporting with independent QA unit audit at defined study milestones.

Study reports are prepared to GLP standard and audited by our QA unit at defined milestones, protocol, raw data and final report, with QA operating on a reporting line entirely independent of the study director and analytical team, in line with GLP principles.

  • GLP-compliant study reporting
  • QA unit independent of study conduct
  • Milestone audits: protocol, raw data, final report
  • Named study director accountable throughout
From£2,800GLP study reporting and QA audit, typical study

Capability datasheet

Five methods side by side

Validated range, precision and accuracy are set out in each validation report, not summarised as a headline figure.

MethodAnalyteMatrixPlatformLLOQValidatedTurnaround
LC-MS/MS Small Molecule BioanalysisSmall-molecule drug & metabolitePlasma, serum, urineLC-MS/MS (triple-quadrupole)Low pg/mL–ng/mL, analyte-dependentICH M10 (2022)15 working days, typical
Ligand-Binding Assays (LBA)Large-molecule therapeutic / biomarkerSerum, plasmaELISA / electrochemiluminescenceAssay-dependent, fixed at validationICH M10, large-molecule provisionsAgreed at study initiation
PK/TK Study BioanalysisStudy-defined PK/TK analytePer study protocolLC-MS/MS or LBA, per methodPer validated methodGLP or non-GLP, per studyTracked to protocol timeline
Immunogenicity Testing (ADA/NAb)Anti-drug antibody (ADA) / NAbSerum, plasmaTiered screen / confirm / titreCut-point set per assayTiered strategy, current guidanceReported alongside PK data
Method Development & ValidationNovel analyte / bespoke matrixStudy-definedDeveloped from first principlesEstablished during developmentFull ICH M10 on completionScoped, fixed-quoted upfront

Scoping

Send the analyte and matrix

Call 01625 838 460 or email the study team.

Bioanalytical lab equipment